Loading...
•
Sep 30, 2022
Editas Q3 2022 Earnings Report
Editas Medicine reported a net loss for Q3 2022 and provided updates on its clinical programs.
Key Takeaways
Editas Medicine reported a net loss of $55.7 million for the third quarter of 2022, compared to a net loss of $39.1 million for the same period in 2021. The company is progressing with its clinical trials for EDIT-301 and EDIT-101 and expects to provide clinical updates in the near future. Cash, cash equivalents, and marketable securities were $478.5 million as of September 30, 2022.
Dosed second patient with EDIT-301 in the Phase 1/2 RUBY trial for sickle cell disease.
On track to announce initial preliminary clinical data from RUBY trial by year-end.
Completed cell editing and currently scheduling first patient dosing with EDIT-301 in Phase 1/2 EDITHAL trial for TDT.
Company to provide a clinical update on the Phase 1/2 BRILLIANCE trial for EDIT-101 this month.
Editas
Editas
Editas Revenue by Segment
Revenue by Segment
Collab & R&D Rev Revenue
CapyFin.com Forward Guidance
Editas Medicine expects that its existing cash, cash equivalents and marketable securities will enable it to fund its operating expenses and capital expenditures into 2024.